



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2275657 C 2010/04/27

(11)(21) **2 275 657**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1997/12/11
(87) Date publication PCT/PCT Publication Date: 1998/07/02
(45) Date de délivrance/Issue Date: 2010/04/27
(85) Entrée phase nationale/National Entry: 1999/06/18
(86) N° demande PCT/PCT Application No.: EP 1997/006926
(87) N° publication PCT/PCT Publication No.: 1998/027817
(30) Priorité/Priority: 1996/12/23 (DE196 54 079.8)

(51) Cl.Int./Int.Cl. *A01N 43/90* (2006.01),
A61K 31/365 (2006.01), *A61K 31/70* (2006.01)

(72) Inventeurs/Inventors:
SIRINYAN, KIRKOR, DE;
DORN, HUBERT, DE;
HEESCHEN, KERSTIN, DE;
HEUKAMP, ULRICH, DE;
KUJANEK, RICHARD, DE

(73) Propriétaire/Owner:
BAYER ANIMAL HEALTH GMBH, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : AGENTS ENDOPARASITICIDES ET ECTOPARASITICIDES
(54) Title: ENDOPARASITICIDAL AND ECTOPARASITICIDAL AGENTS

(57) **Abrégé/Abstract:**

The present invention relates to mixtures of avermectins, 22,23-dihydroavermectin B₁ (ivermectin) and milbemycins from the class of the macrocyclic lactones with agonists or antagonists of the nicotinic acetylcholine receptors of insects, optionally in the presence of diluents or excipients.



30725-187

Abstract

The present invention relates to mixtures of avermectins, 22,23-dihydroavermectin B₁ (ivermectin) and milbemycins from the class of the macrocyclic lactones with
5 agonists or antagonists of the nicotinergetic acetylcholine receptors of insects, optionally in the presence of diluents or excipients.

30725-187

- 1 -

Endoparasiticial and ectoparasiticial agents

The present invention relates to mixtures of avermectins, 22,23-dihydroavermectins B₁ (ivermectins) and milbemycins from the class of the macrocyclic lactones with agonists or antagonists of the nicotinic acetylcholine receptors of insects for controlling ecto- and endoparasites.

Gastrointestinal nematode infections of dogs are in most cases brought about by species of the three nematode families Ascarididae, Ancylostomatidae and Trichuridae. In cats, it is predominantly the two nematode families Ascarididae and Ancylostomatidae which occur worldwide. After passing through a number of development stages in a very great diversity of tissues of the host animals, patent infection of the gastrointestinal tract occurs. During the prepatency and patency of the infection, the parasitosis of round worms, hook worms and whip worms causes considerable problems, especially in young, growing dogs, cats and also in humans. Therapy or prophylactic treatment is therefore in urgent necessity in order both to cure animals already affected and to maintain as yet unaffected animals in a healthy condition.

Consequently, the protection of dogs and cats against infection is of very great importance as prophylaxis against infections of humans, in particular of children.

Particular mention must be made of the parasite Dirofilaria immitis - a Filaria endemic in parts of North to South America, Africa, Asia and also Australia. This parasite is the cause of the important canine and feline cardiovascular dirofilariosis. The severe pathophysiological changes within the cardiovascular system which occur during the Dirofilaria immitis infection of dogs and cats can bring about a dramatic course of the disease in the host animal.

The anthelmintics ivermectin/milbemycin from the class of the macrocyclic lactones show activity against Dirofilaria immitis in dogs and cats. These active compounds are usually administered orally or parenterally.

- 2 -

Flea infestations of pets such as dogs and cats are not only a nuisance for the infected animals, but they also cause considerable pain (sting injuries, itching and allergies) and damage (loss of blood) to the affected animals. Fleas can also transmit various species of tapeworms. They therefore also pose a medical problem for the infected animals and
5 also for the animal keepers. The animal keeper can also be attacked by fleas. In some humans, this causes flea sting allergy. An effective control of fleas in dogs and cats has therefore always been desirable and necessary, in particular since the number of these pets is increasing and they live in ever closer contact with humans.

A large number of insectidically active compounds for controlling fleas have become
10 known to date. Such active compounds are, for example, from the class of the carbamates (propoxur, bendiocarb, carbaryl), from the class of the phosphoric esters (fenthione, diazinone) and from the class of the pyrethroids (permethrin, cypermethrin, resmethrin).

These active compounds are dermally administered contact insecticides which act
15 predominantly on adult fleas.

For the protection of pets against both problems, two separate treatments (parenteral or oral treatment against endoparasites, dermal treatment against ectoparasites) have been customary hitherto. It was desirable to replace these two treatments by one single treatment.

20 Combination products, usually for widening the spectrum of activity in the use against endoparasites, are already known.

Hitherto, a combined administration of endoparasitocides and ectoparasitocides has not been customary in practice.

30725-187

- 2a -

In one aspect, the invention provides use of an avermectin, a 22,23-dihydroavermectin (an ivermectin) or a milbemyacin in combination with an agonist or antagonist of the nicotinerbic receptors of insects for controlling ecto-
5 and endoparasites.

In a further aspect, the invention provides use of an avermectin, a 22,23-dihydroavermectin (an ivermectin) or a milbemyacin in combination with an agonist or antagonist of the nicotinerbic receptions of insects for preparing a
10 medicament for controlling ecto- and endoparasites.

In a further aspect, the invention provides a composition comprising a combination of an avermectin, a 22,23-dihydroavermectin (an ivermectin) or a milbemyacin with an agonist or antagonist of the nicotinerbic acetylcholine
15 receptors of insects, and optionally a diluent or excipient for controlling ecto- and endoparasites.

In a still further aspect, the invention provides a composition comprising a combination of an avermectin, a 22,23-dihydroavermectin (an ivermectin) or a milbemyacin with
20 an agonist or antagonist of the nicotinerbic acetylcholine receptors of insects, and optionally a diluent or excipient for preparing a medicament for controlling ecto- and endoparasites.

In a yet further aspect, the invention provides a
25 commercial package comprising the above defined combination or composition and associated therewith instructions for controlling ecto- and endoparasites.

The present invention provides compositions comprising at least one avermectin, 22,23-dihydroavermectin B₁
30 (ivermectins) or milbemyacin from the class of the macrocyclic lactones with agonists or antagonists of the nicotinerbic acetylcholine receptors of

30725-187

- 3 -

insects.

Surprisingly, these active compounds which originate from entirely different chemical classes and which have entirely different biological activities influence each other synergistically.

- 5 The use of avermectins, 22,23-dihydroavermectins B₁ (ivermectins) and milbemycins from the class of the macrocyclic lactones as endoparasitocides has been known for a long time and is the subject of numerous patent applications and review articles (for example biological effects in: Ivermectin and Abamectin, W. C. Campbell, Ed., Springer Verlag, New York, N. Y., 1989; Avermectins and Milbemycins Part II, 10 H. G. Davies et al., Chem. Soc. Rev. 20 (1991) p. 271-339; Chemical Modifications in: G. Lukacs et al. (Eds.), Springer-Verlag, New York, (1990), Chapter 3; Cydectin™ [moxidectin and derivatives]: G. T. Carter et al., J. Chem. Soc. Chem. Commun. (1987), p. 402-404); EP 423 445-A1). The use of doramectin (Pfizer) as an endoparasiticide is also known (cf. "Doramectin - a potent novel endectozide" 15 A. C. Goudie et al., Vet. Parasitol. 49 (1993), p. 5-15).

- Furthermore, combinations of avermectins, 22,23-dihydroavermectins B₁ (ivermectins) or milbemycins with certain classes of anthelmintics such as, for example, benzimidazoles, salicylamides, levamisole, pyrantel or praziquantel are the subject of numerous patent applications (for example: GB 2 252 730; GB 2 224 933; 20 GB 2 21 3 722; EP-A 59 074).

Examples of avermectins and derivatives thereof include mixtures of macrolide lactones of the general formula (Ia)

Macrocyclic lactone	$-C_{22}R^1-X-C_{23}R^2-$	R^3	R^4
Avermectin A _{1a}	$-\text{CH}=\text{CH}-$	-sec-Bu	-Me
Avermectin A _{1b}	$-\text{CH}=\text{CH}-$	-iso-Pr	-Me
Avermectin A _{2a}	$-\text{CH}_2-\text{CHOH}-$	-sec-Bu	-Me
Avermectin A _{2b}	$-\text{CH}_2-\text{CHOH}-$	-iso-Pr	-Me
Avermectin B _{1a}	$-\text{CH}=\text{CH}-$	-sec-Bu	-H
Avermectin B _{1b}	$-\text{CH}=\text{CH}-$	-iso-Pr	-H

30725-187

- 5 -

5

Avermectin B _{2a}	-CH ₂ -CHOH-	-sec-Bu	-H
Avermectin B _{2b}	-CH ₂ -CHOH-	-iso-Pr	-H
22,23-Dihydroavermectin B _{1a}	-CH ₂ -CH ₂ -	-sec-Bu	-H
22,23-Dihydroavermectin B _{1b}	-CH ₂ -CH ₂ -	-iso-Pr	-H
Doramectin	-CH=CH-	-Chx	-H

22,23-Dihydroavermectin B₁ represents ivermectin B₁;

sec-Bu = secondary butyl; iso-Pr = isopropyl; Chx = cyclohexyl; -Me = methyl

10

The avermectins and 22,23-dihydroavermectins B₁ (ivermectins) of the general formula (Ia) are generally employed as mixtures. Of particular interest in this context is the product abamectin, which essentially comprises the avermectins B₁, and hydrogenation products thereof, the 22,23-dihydroavermectins B₁ (ivermectin).

15

The compounds labelled "b" among the macrocyclic lactones, which possess an iso-propyl radical in the C₂₅ position, need not necessarily be separated from the "a" compounds, which have a sec-butyl group in the C₂₅ position. Generally, the mixture of both substances is isolated, consisting of > 80% sec-butyl derivative (B_{1a}) and < 20% iso-propyl derivative (B_{1b}), and can be used in accordance with the invention. Moreover, in the case of the stereoisomers, the substituents in the C₁₃ and C₂₃ position can be arranged in both α and β configuration on the ring system, i.e. they can be located above or below the plane of the molecule.


20

The milbemycins have the same macrolide ring structure as the avermectins or 22,23-dihydroavermectins B₁ (ivermectins), but carry no substituent (i.e. missing oleandrose disaccharide fragment) in position 13 (R⁵ = hydrogen).

Examples of milbemycins of the class of the macrocyclic lactones include the compounds of the general formula (IIa)

30725-187



- 6 -



in which

radicals R¹ to R⁵ are each as defined in Table 2 below:

Table 2

Macrocyclic lactone	R ¹	R ²	R ³	R ⁴	R ⁵
Milbemycin B41 D	-H	-H	-iso-Pr	-H	-H
Nemadectin	-H	-OH		-H	-H
Moxidectin	-H	=N-O-Me		-H	-H

iso-Pr = isopropyl

Particularly suitable co-components for the mixtures according to the invention are:

Avermectin B_{1a}/B_{1b};

22,23-Dihydroavermectin B_{1a}/B_{1b} (or ivermectin B_{1a}/B_{1b});

30725-187

- 7 -

Doramectin;


Moxidectin.

Agonists or antagonists of the nicotinic acetylcholine receptors of insects are known, for example from the European laid-open applications No. 464 830, 428 941, 425 978, 386 565, 383 091, 375 907, 364 844, 315 826, 259 738, 254 859, 235 725, 212 600, 192 060, 163 855, 154 178, 136 636, 303 570, 302 833, 306 696, 189 972, 455 000, 135 956, 471 372, 302 389; the German laid-open applications No. 3 639 877, 3 712 307; the Japanese laid-open applications No. 03 220 176, 02 207 083, 63 307 857, 63 287 764, 03 246 283, 04 009 371, 03 279 359, 03 255 072; US patents
 10 No. 5 034 524, 4 948 798, 4 918 086, 5 039 686, 5 034 404; PCT applications No. WO 91/17 659, WO 91/4965; the French application No. 2 611 114; the Brazilian application No. 88 03 621.

The formulae and definitions described in these publications and the individual preparations and compounds described therein are useful for this invention.

15

These compounds are preferably represented by the general formula (I)



in which

R represents hydrogen, or represents optionally substituted radicals from the group consisting of acyl, alkyl, aryl, aralkyl, heteroaryl and heteroarylalkyl;

20 A represents a monofunctional group from the group consisting of hydrogen, acyl, alkyl and aryl or represents a bifunctional group linked to the radical Z;

E represents an electron-withdrawing radical;

X represents the radicals -CH= or =N- where the radical -CH= may be linked to the radical Z instead of an H atom;

Z represents a monofunctional group from the group consisting of alkyl, -O-R,

5 -S-R and $\text{---N} \begin{array}{l} \text{R} \\ \text{R} \end{array}$

or represents a bifunctional group linked to the radical A or to the radical X.

Particular preference is given to compounds of the formula (I) in which the radicals are as defined below:

10 R represents hydrogen and represents optionally substituted radicals from the group consisting of acyl, alkyl, aryl, aralkyl, heteroaryl and heteroarylalkyl.

Suitable acyl radicals include formyl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, (alkyl-)-(aryl-)-phosphoryl, each of which may in turn be substituted.

15 Suitable alkyl includes C₁₋₁₀-alkyl, in particular C₁₋₄-alkyl, specifically methyl, ethyl, i-propyl, sec.- or t-butyl, each of which may in turn be substituted.

Suitable aryl includes phenyl and naphthyl, in particular phenyl.

Suitable arylalkyl includes phenylmethyl and phenethyl.

20 Suitable heteroaryl includes heteroaryl having up to 10 ring atoms and N, O and S, in particular N, as hetero atoms. Specific examples are thienyl, furyl, thiazolyl, imidazolyl, pyridyl and benzothiazolyl.

Suitable heteroarylalkyl includes heteroarylmethyl, heteroarylethyl having up to 6 ring atoms and N, O and S, in particular N, as hetero atoms.

Examples of preferred substituents are:

alkyl preferably having from 1 to 4, in particular 1 or 2, carbon atoms, such as
5 methyl, ethyl, n- and i-propyl and n-, i- and t-butyl; alkoxy preferably having
1 to 4, in particular 1 or 2, carbon atoms, such as methoxy, ethoxy, n-, and i-
propyloxy and n-, i- and t-butyloxy; alkylthio preferably having 1 to 4, in
particular 1 or 2, carbon atoms, such as methylthio, ethylthio, n- and i-
propylthio and n-, i- and t-butylthio; halogenoalkyl preferably having 1 to 4, in
10 particular 1 or 2, carbon atoms and preferably 1 to 5, in particular 1 to 3,
halogen atoms, where the halogen atoms are identical or different and are
preferably fluorine, chlorine or bromine, in particular fluorine, such as
trifluoromethyl; hydroxyl; halogen, preferably fluorine, chlorine, bromine and
iodine, in particular fluorine, chlorine and bromine; cyano; nitro; amino;
15 monoalkyl- and dialkylamino preferably having 1 to 4, in particular 1 or 2,
carbon atoms per alkyl group, such as methylamino, methyl-ethyl-amino, n- and
i-propylamino and methyl-n-butylamino; carboxyl, carbalkoxy preferably having
2 to 4, in particular 2 or 3, carbon atoms, such as carbomethoxy and
carboethoxy; sulfo ($-\text{SO}_3\text{H}$); alkylsulfonyl preferably having 1 to 4, in particular
20 1 or 2, carbon atoms, such as methylsulfonyl and ethylsulfonyl; arylsulfonyl
preferably having 6 or 10 arylcarbon atoms, such as phenylsulfonyl, and
heteroarylamino and heteroarylalkylamino, such as chloropyridylamino and
chloropyridylmethylamino.

A particularly preferably represents hydrogen and represents optionally substituted
25 radicals from the group consisting of acyl, alkyl and aryl, each of which are
preferably as defined under R. Furthermore, A represents a bifunctional group.
Suitable bifunctional groups include optionally substituted alkylene having 1-4,
in particular 1-2, carbon atoms, suitable substituents being the substituents listed
further above, it being possible for the alkylene groups to be interrupted by
30 hetero atoms from the group consisting of N, O and S.

A and Z together with the atoms to which they are attached may form a saturated or unsaturated heterocyclic ring. The heterocyclic ring may contain 1 or 2 more identical or different hetero atoms and/or hetero groups. Preferred hetero atoms are oxygen, sulfur or nitrogen and preferred hetero groups are N-alkyl, the alkyl
 5 of the N-alkyl group preferably containing 1 to 4, in particular 1 or 2, carbon atoms. Suitable alkyl includes methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to 7, preferably 5 or 6, ring members.

Examples of the heterocyclic ring include pyrrolidine, piperidine, piperazine, hexamethyleneimine, hexahydro-1,3,5-triazine and morpholine, each of which
 10 is optionally substituted, preferably by methyl.

E represents an electron-withdrawing radical; particular preference is given to NO₂, CN and halogenoalkylcarbonyl such as 1,5-halogeno-C₁₋₄-carbonyl, in particular COCF₃.

X represents -CH= or -N=

15 Z represents the optionally substituted radicals alkyl, -OR, -SR and -NRR, where R and the substituents are preferably as defined above.



Z may, in addition to the abovementioned ring, together with the atom to which

it is attached and the radical $\begin{array}{c} | \\ =\text{C}- \end{array}$

20 in the position of X form a saturated or unsaturated heterocyclic ring. The heterocyclic ring may contain 1 or 2 more identical or different hetero atoms and/or hetero groups. Preferred hetero atoms are oxygen, sulfur or nitrogen and preferred hetero groups are N-alkyl, the alkyl or N-alkyl group preferably containing 1 to 4, in particular 1 or 2, carbon atoms. Suitable alkyl includes methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring
 25 contains 5 to 7, preferably 5 or 6, ring members.

Examples of the heterocyclic ring include pyrrolidine, piperidine, piperazine, hexamethylenimine, morpholine and N-methylpiperazine.

Very particularly preferred compounds utilizable according to the invention are compounds of the general formulae (II) and (III):





5 in which



n represents 1 or 2,

subst. represents one of the substituents listed above, in particular halogen, especially chlorine,





A, Z, X and E are as defined above.











10 Specific examples are the following compounds:









AKD 1022







Ti 435

Very particular preference is given to the compounds imidacloprid, Ti 435 and AKD 1022.

For example, the 22,23-dihydroavermectins B_{1a}/B_{1b} (ivermectins B_{1a}/B_{1b}) of the general formula (Ia) from the class of the macrocyclic lactones




R⁵ represents methyl and ethyl

are combined as co-components according to the invention with imidacloprid, if appropriate in the presence of other active compounds and carriers, in a synergistic ratio.

For example, the 22,23-dihydroavermectins B_{1a}/B_{1b} (ivermectins B_{1a}/B_{1b}) of the general formula (Ia) from the class of the macrocyclic lactones

30725-187

- 16 -



in which

R⁵ represents methyl and ethyl

are combined as co-components according to the invention with Ti 435, if appropriate in the presence of other active compounds and carriers, in a synergistic ratio.

- 5 The endoparasitidal activity of the active compound combinations according to the invention is significantly higher than was to be expected from the activities of the individual components. Therefore, by employing these combinations, it is possible to reduce the application rate and the number of applications.

Having low toxicity to warm-blooded species, the compositions according to the invention are suitable for controlling pathogenic endoparasites and ectoparasites which occur in humans and in animal keeping and animal breeding, in productive animals, breeding animals, zoo animals, laboratory animals, animals for experimentation and pets. They are active against all or individual stages of development of the pests and against resistant and normally sensitive species. By controlling the pathogenic endoparasites the intention is to reduce disease, mortality and reductions in yield, so that the use of the active compounds enables more economical and simpler animal keeping. The pathogenic endoparasites include nematodes and Acantocephalea. in

particular:

From the subclass of the Monogenea, e.g. Gyrodactylus spp., Dactylogyrus spp., Polystoma spp..

5 From the order of the Enoplida e.g.: Trichuris spp., Capillaria spp., Trichomosoides spp., Trichinella spp..

From the order of the Rhabditia e.g.: Micronema spp., Strongyloides spp..

10 From the order of the Strongylida e.g.: Strongylus spp., Triodontophorus spp., Oesophagodontus spp., Trichonema spp., Gyallocephalus spp., Cyndropharynx spp., Poterostomum spp., Cyclococercus spp., Cylicostephanus spp., Oesophagostomum spp., Chabertia spp., Stephanurus spp., Ancylostoma spp., Uncinaria spp., Bunostomum spp.,

15 Globocephalus spp., Syngamus spp., Cyathostoma spp., Metastrongylus spp., Dictyocaulus spp., Muellerius spp., Protostrongylus spp., Neostongylus spp., Cystocaulus spp., Pneumostongylus spp., Spicocaulus spp., Elaphostongylus spp., Parelaphostongylus spp., Crenosoma spp., Paracrenosoma spp., Angiostrongylus spp., Aelurostrongylus spp., Filaroides spp., Parafilaroides spp., Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Marshallagia spp., Cooperia spp., Nematodirus spp., Hyostongylus spp., Obeliscoides spp., Amidostomum spp., Ollulanus spp..

From the order of the Oxyurida e.g.: Oxyuris spp., Enterobius spp., Passalurus spp., Syphacia spp., Aspicularis spp., Heterakis spp..

20 From the order of the Ascaridia e.g.: Ascaris spp., Toxascaris spp., Toxocara spp., Parascaris spp., Anisakis spp., Ascaridia spp..

From the order of the Spirurida e.g.: Gnathostoma spp., Physaloptera spp., Thelazia spp., Gongylonema spp., Habronema spp., Parabronema spp., Draschia spp., Dracunculus spp..

From the order of the Filariida e.g.: *Stephanofilaria* spp., *Parafilaria* spp., *Setaria* spp., *Loa* spp., *Dirofilaria* spp., *Litomosoides* spp., *Brugia* spp., *Wuchereria* spp., *Onchocerca* spp..

5 From the order of Gigantorhynchida e.g.: *Filicollis* spp., *Moniliformis* spp., *Macracanthorhynchus* spp., *Prosthenorchis* spp..

The ectoparasites include:

from the order of the Anoplura, e.g.: *Haematopinus* spp., *Linognathus* spp., *Solenopotes* spp., *Pediculus* spp., *Pthirus* spp.;

10 from the order of the Mallophaga, e.g.: *Trimenopon* spp., *Menopon* spp., *Ecomenacanthus* spp., *Menacanthus* spp., *Trichodectes* spp., *Felicola* spp., *Damalinea* spp., *Bovicola* spp.;

15 from the order of the Diptera, e.g.: *Chrysops* spp., *Tabanus* spp., *Musca* spp., *Hydrotaea* spp., *Muscina* spp., *Haematobosca* spp., *Haematobia* spp., *Stomoxys* spp., *Fannia* spp., *Glossina* spp., *Lucilia* spp., *Calliphora* spp., *Auchmeromyia* spp., *Cordylobia* spp., *Cochliomyia* spp., *Chrysomyia* spp., *Sarcophaga* spp., *Wohlfartia* spp., *Gasterophilus* spp., *Oesteromyia* spp., *Oedemagena* spp., *Hypoderma* spp., *Oestrus* spp., *Rhinoestrus* spp., *Melophagus* spp., *Hippobosca* spp..

From the order of the Siphonaptera, e.g.: *Ctenocephalides* spp., *Echidnophaga* spp., *Ceratophyllus* spp..

20 Particular emphasis is given to the activity against Siphonaptera, in particular against fleas.

25 The productive and breeding animals include mammals such as cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer and reindeer, fur-bearing animals such as mink, chinchilla and raccoon, birds such as hens, geese, turkeys and ducks, fresh- and salt-water fish such as trout, carp and eels.

Laboratory and experimental animals include mice, rats, guinea-pigs, golden hamsters,

dogs and cats.

The pets include dogs and cats.

Administration can be carried out both prophylactically and therapeutically.

Administration of the active compounds is carried out directly or in the form of
5 suitable preparations, orally or dermally. Dermal administration is particularly preferred.

Enteral administration of the active compounds is carried out, for example, orally in the
form of powders, tablets, capsules, pastes, drinks, granules, orally administrable
solutions, suspensions and emulsions, boluses, medicated feed or drinking water.
Dermal administration is carried out, for example, in the form of spraying or pouring-
10 on and spotting-on.

Suitable preparations are:

solutions such as oral solutions, concentrates for oral administration after dilution,
solutions for use on the skin or in body cavities, pouring-on formulations, gels;

emulsions and suspensions for oral or dermal administration; semi-solid preparations;

15 formulations in which the active compound is processed in an ointment base or in an
oil-in-water or water-in-oil emulsion base;

Solid preparations such as powders, premixes or concentrates, granules, pellets, tablets,
boluses, capsules; aerosols and inhalants, active compound-containing shaped articles.

Solvents which may be mentioned are: physiologically tolerable solvents such as water,
20 alcohols such as ethanol, butanol, benzyl alcohol, glycerol, propylene glycol,
polyethylene glycols, N-methyl-pyrrolidone, 2-pyrrolidone, and mixtures thereof.

The active compounds can optionally also be dissolved in physiologically tolerable vegetable or synthetic oils which are suitable for injection.

Solubilizers which may be mentioned are: solvents which promote the dissolution of the active compound in the main solvent or prevent its precipitation. Examples are
5 polyvinylpyrrolidone, polyvinyl alcohol, polyoxyethylated castor oil, polyoxyethylated sorbitan ester.

Preservatives are: benzyl alcohol, trichlorobutanol, p-hydroxybenzoic acid esters, n-butanol.

Oral solutions are administered directly. Concentrates are administered orally after prior
10 dilution to the use concentration. Oral solutions and concentrates are prepared according to the state of the art, sterile procedures not being necessary.

Solutions for use on the skin are trickled on, spread on, rubbed in, sprinkled on or sprayed on.

It may be advantageous to add thickeners during preparation. Thickeners are: inorganic
15 thickeners such as bentonites, colloidal silicic acid, aluminium monostearate, organic thickeners such as cellulose derivatives, polyvinyl alcohols and their copolymers, acrylates and methacrylates.

Gels are applied to or spread on the skin or introduced into body cavities. Gels are prepared by treating solutions which have been prepared as described in the case of the
20 injection solutions with sufficient thickener that a clear material having an ointment-like consistency results. The thickeners employed are the thickeners given above.

Pour-on formulations are poured or sprayed onto limited areas of the skin, the active compound penetrating the skin and acting systemically.

Pour-on formulations are prepared by dissolving, suspending or emulsifying the active

compound in suitable skin-compatible solvents or solvent mixtures. If appropriate, other auxiliaries such as colorants, bioabsorption-promoting substances, antioxidants, light stabilizers, adhesives are added.

Solvents which may be mentioned are: water, alkanols, glycols, polyethylene glycols,
5 polypropylene glycols, glycerol, aromatic alcohols such as benzyl alcohol, phenylethanol, phenoxyethanol, esters such as ethyl acetate, butyl acetate, benzyl benzoate, ethers such as alkylene glycol alkyl ethers such as dipropylene glycol monomethyl ether, diethylene glycol mono-butyl ether, ketones such as acetone, methyl ethyl ketone, cyclic carbonates such as propylene carbonate, ethylene carbonate,
10 aromatic and/or aliphatic hydrocarbons, vegetable or synthetic oils, DMF, dimethylacetamide, n-alkylpyrrolidones such as methylpyrrolidone, n-butylpyrrolidone or n-octylpyrrolidone, N-methylpyrrolidone, 2-pyrrolidone, 2,2-dimethyl-4-oxy-methylene-1,3-dioxolane and glycerol formal.

Colorants are all colorants permitted for use on animals and which can be dissolved or
15 suspended.

Absorption-promoting substances are, for example, DMSO, spreading oils such as isopropyl myristate, dipropylene glycol pelargonate, silicone oils and copolymers thereof with polyethers, fatty acid esters, triglycerides, fatty alcohols.

Antioxidants are sulfites or metabisulfites such as potassium metabisulfite, ascorbic
20 acid, butylhydroxytoluene, butylhydroxyanisole, tocopherol.

Light stabilizers are, for example, novantisolic acid.

Adhesives are, for example, cellulose derivatives, starch derivatives, polyacrylates, natural polymers such as alginates, gelatin.

Emulsions can be administered orally, dermally or as injections.

Emulsions are either of the water-in-oil type or of the oil-in-water type.

They are prepared by dissolving the active compound either in the hydrophobic or in the hydrophilic phase and homogenizing this with the solvent of the other phase with the aid of suitable emulsifiers and, if appropriate, other auxiliaries such as colorants, absorption-promoting substances, preservatives, antioxidants, light stabilizers, viscosity-enhancing substances.

Hydrophobic phases (oils) which may be mentioned are: liquid paraffins, silicone oils, natural vegetable oils such as sesame oil, almond oil, castor oil, synthetic triglycerides such as caprylic/capric biglyceride, triglyceride mixture with vegetable fatty acids of the chain length C_{8-12} or other specially selected natural fatty acids, partial glyceride mixtures of saturated or unsaturated fatty acids possibly also containing hydroxyl groups, mono- and diglycerides of the C_8/C_{10} fatty acids.

Fatty acid esters such as ethyl stearate, di-n-butyryl adipate, hexyl laurate, dipropylene glycol perlargonate, esters of a branched fatty acid of medium chain length with saturated fatty alcohols of chain length $C_{16}-C_{18}$, isopropyl myristate, isopropyl palmitate, caprylic/capric acid esters of saturated fatty alcohols of chain length $C_{12}-C_{18}$, isopropyl stearate, oleyl oleate, decyl oleate, ethyl oleate, ethyl lactate, waxy fatty acid esters such as synthetic duck coccygeal gland fat, dibutyl phthalate, diisopropyl adipate, ester mixtures related to the latter, inter alia.

Fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol, oleyl alcohol.

Fatty acids such as oleic acid and its mixtures.

Hydrophilic phases which may be mentioned are:

water, alcohols such as propylene glycol, glycerol, sorbitol and its mixtures.

Emulsifiers which may be mentioned are: non-ionic surfactants, e.g. polyethoxylated

castor oil, polyethoxylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethyl stearate, alkylphenol polyglycol ether;

ampholytic surfactants such as di-Na N-lauryl- β -iminodipropionate or lecithin;

anionic surfactants, such as Na lauryl sulfate, fatty alcohol ether sulfates, mono/dialkyl
5 polyglycol ether orthophosphoric acid ester monoethanolamine salt;

cation-active surfactants, such as cetyltrimethylammonium chloride.

Further auxiliaries which may be mentioned are: substances which enhance the viscosity and stabilize the emulsion, such as carboxymethylcellulose, methylcellulose and other cellulose and starch derivatives, polyacrylates, alginates, gelatin, gum arabic,
10 polyvinylpyrrolidone, polyvinyl alcohol, copolymers of methyl vinyl ether and maleic anhydride, polyethylene glycols, waxes, colloidal silicic acid or mixtures of the substances mentioned.

Suspensions can be administered orally or dermally. They are prepared by suspending the active compound in a suspending agent, if appropriate with addition of other
15 auxiliaries such as wetting agents, colorants, bioabsorption-promoting substances, preservatives, antioxidants, light stabilizers.

Liquid excipients which may be mentioned are all homogeneous solvents and solvent mixtures.

Wetting agents (dispersants) which may be mentioned are the surfactants given above.

20 Other auxiliaries which may be mentioned are those given above.

Semi-solid preparations can be administered orally or dermally. They differ from the suspensions and emulsions described above only by their higher viscosity.

For the production of solid preparations, the active compound is mixed with suitable excipients, if appropriate with addition of auxiliaries, and brought into the desired form.

Excipients which may be mentioned are all physiologically tolerable solid inert substances. Those used are inorganic and organic substances. Inorganic substances are,
5 for example, sodium chloride, carbonates such as calcium carbonate, hydrogencarbonates, aluminium oxides, titanium oxide, silicic acids, argillaceous earths, precipitated or colloidal silica, phosphates.

Organic substances are, for example, sugar, cellulose, foodstuffs and feeds such as milk powder, animal meal, grain meals and shreds, starches.

10 Auxiliaries are preservatives, antioxidants, colorants which have already been mentioned above.

Other suitable auxiliaries are lubricants and glidants such as magnesium stearate, stearic acid, talc, bentonites, disintegration-promoting substances such as starch or crosslinked polyvinylpyrrolidone, binders such as starch, gelatin or linear polyvinylpyrrolidone, and
15 dry binders such as microcrystalline cellulose.

The active compounds can also be present in the preparations as a mixture with synergists or with other active compounds which act against pathogenic endoparasites. Such active compounds are, for example, L-2,3,5,6-tetrahydro-6-phenylimidazothiazole, benzimidazole carbamates, pyrantel, praziquantel, epsiprantel.

20 Ready-to-use preparations contain the compounds acting against ectoparasites in concentrations of 10 ppm - 20 per cent by weight, preferably from 0.1 - 12.5 per cent by weight.

Preparations which are diluted before use contain the compounds acting against ectoparasites in concentrations of 0.5 - 90 % by weight, preferably of 5 - 50 % by
25 weight.

Furthermore, the preparations comprise the above-described active compounds against endoparasites in concentrations of 10 ppm - 2% by weight, preferably of 0.05 - 0.9% by weight, very particularly preferably of 0.005 - 0.25% by weight.

5 When used in the pet dog, the weight ratio of macrocyclic lactone to agonist or antagonist of the nicotinic acetylcholine receptors of insects in the compositions according to the invention is generally 1:500 to 1000, preferably 1:500 to 850 and very particularly preferably 1:500.

10 Finally, when used in useful animals, the weight ratio of macrocyclic lactone to agonist or antagonist of the nicotinic acetylcholine receptors of insects in the compositions according to the invention is generally 1:20 to 400, preferably 1:20 to 250 and very particularly preferably 1:20 to 50.

In the examples below, the agonist or antagonist of the nicotinic acetylcholine receptors of insects is 1-[(6-chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinium (common name imidacloprid) and the macrocyclic lactone is ivermectin.

Examples

Example 1

SL formulation (water-soluble concentrate)

- | | | |
|---|--------|---|
| | 18.3 g | of imidacloprid |
| 5 | 0.2 g | of ivermectin |
| | 2.5 g | of a neutral emulsifier based on alkylaryl polyglycol ether |
| | 3.5 g | of diisooctyl sulfosuccinate, sodium salt |
| | 38.4 g | of dimethyl sulfoxide and |
| | 37.5 g | of 2-propanol |

10 **Example 2**

Pour-on formulation

- | | | |
|----|--------|--|
| | 20.3 g | of imidacloprid |
| | 0.2 g | of ivermectin |
| | 1.8 g | of polyvinyl alcohol |
| 15 | 1.8 g | of a block copolymer based on ethylene oxide and propylene oxide |
| | 0.26 g | of xanthan gum |
| | 9.0 g | of glycerol |
| | 59.2 g | of distilled water |

Example 3

20 Spot-on formulation

- | | | |
|--|----------|-------------------|
| | 10.000 g | of imidacloprid |
| | 0.006 g | of ivermectin |
| | 83.394 g | of benzyl alcohol |

16.300 g of propylene carbonate
0.100 g of BHT (butylated hydroxytoluene)

Example 4

Spot-on formulation

5 10.000 g of imidacloprid
 0.050 g of ivermectin
 83.350 g of benzyl alcohol
 16.300 g of propylene carbonate
 0.100 g of BHT

10 **Example 5**

Spot-on formulation:

 10.000 g of imidacloprid
 0.200 g of ivermectin
 83.200 g of benzyl alcohol
15 16.300 g of propylene carbonate
 0.100 g of BHT

Use Example A

1 ml of the SL formulation of Example 1 was applied as a solution by pouring onto the shoulder of a dog infested with 200 fleas. The test animal was immediately free of
20 adult fleas. The treatment according to the invention leads to a flea mortality rate of 100%.

Use Example B

1 ml of the formulation of Example 1 was diluted in 1 l of water and this solution was poured over dogs of about 20 kg weight infested with fleas until they were dripping wet. The following results were obtained:

5 **Table B**

Period of time Day	Number of fleas per dog		% activity
	Untreated	Treated	
-1 Infestation with 100 fleas			
0 Treatment and count	30	0	100
5, 8 Infestation with 100 fleas			
9 Count	56	0	100
15 Infestation with 100 fleas			
16 Count	76	0	100
19 Infestation with 100 fleas (untreated animals) 250 fleas (treated animals)			
20 Count	39	0	100
26 Infestation with 100 fleas			
27 Count	43	0	100

Use Example C

In vivo nematode test

Nematospiroides dubius in mice

Mice were experimentally infected with nematodes of the species Nematospiroides
5 dubius. Specifically, the mice were administered Nematospiroides dubius orally as
60 filariform larvae.

After the prepatency period had expired, the suspended active compounds of Example
2 were administered orally on day 12 after the infection.

Determination of the activity:

10 The mice are selected on day 20 after the infection. The adult parasites in the
Duodenum are counted by means of a compressorium. The success of treatment in the
dose group is compared to the untreated control group.

Tables A and B below indicate the action of the combination against Nematospiroides
dubius in mice.

Table C Action of the combination of imidacloprid and ivermectin B_{1a}/B_{1b} against Nematospiroides dubius in mice after oral administration

Active compound and amount [mg/kg]		Reduction rate [%]
5	Imidacloprid	50.0
	Ivermectin B _{1a} /B _{1b}	0.1
	Ivermectin B _{1a} /B _{1b} + imidacloprid	100
10	Imidacloprid	25.0
	Imidacloprid + ivermectin b _{1a} /B _{1b}	0.1
		>80

Example D

In vivo nematode test

Heterakis spumosa in mice

Mice were experimentally infected with nematodes of the species Heterakis spumosa. Specifically, the mice were administered Heterakis spumosa orally as 90 embryonate eggs.

After the prepatency period had expired, the suspended active compounds of Example 2 were administered orally on day 46 after the infection.

Determination of the activity:

The mice are selected on day 54 after the infection. The adult parasites are counted in the colon and caecum using a microscope. The success of treatment in the dose group is compared to the untreated control group.

5 The table below indicates the action of the combination against Heterakis spumosa in mice.

Table D Action of the combination of imidacloprid and ivermectin B_{1a}/B_{1b} against Heterakis spumosa in mice after oral administration

Active compound and amount [mg/kg]		Reduction rate [%]
10	Imidacloprid	50.0
	Ivermectin B _{1a} /B _{1b}	0.1
	Imidacloprid + ivermectin B _{1a} /B _{1b}	0.1
15	Imidacloprid	25.0
	Imidacloprid + ivermectin B _{1a} /B _{1b}	25.0
	Imidacloprid	10.0
20	Imidacloprid + ivermectin B _{1a} /B _{1b}	10.0
	Imidacloprid	5.0
	Imidacloprid + ivermectin B _{1a} /B _{1b}	5.0

Use Example E

The insecticidal and nematocidal activity of three imidacloprid/ivermectin formulations

was compared in four groups of test dogs using constant application volumina of 0.1 ml/kg. The test substances were administered by spot-on. The percentage ivermectin in the formulations was accordingly 0.006%, 0.05% and 0.2%. Each of the test substances comprised a constant percentage of 10% imidacloprid. All animals of the
5 respective treatment and control groups were clinically examined for flea and nematode infestation at defined intervals before and after the treatment.

Test period: 4 weeks

Test substances:

I. Imidacloprid

10 Content of a.i.: 10% w/v

II. Ivermectin

Content of a.i.: 0.006% w/v (Example E1)
0.05% w/v (Example E2)
0.2% w/v (Example E3)

15 **Test animals**

Species: dog (*Canis familiaris*)
Breed: Beagle
Number: 8
Sex: 4 female and 4 male animals
20 Age: puppies: 2-3 months old

Experimental infestation with fleas

Each dog was infested in the region of the inner thigh fold with about 100 fleas, which were up to four weeks old, on day -3 before the treatment. Reinfestations were carried out every week.

Experimental infestation with nematodes

20 days before the treatment, each dog was infected with 250 infectious larvae (1,3) of *Acylostoma caninum*.

Administration

- 5 The animals were treated once using the spot-on method. A treatment group was in each case formed by two animals. The administration volume was 0.1 ml/kg for all animals.

Clinical examination of the activity

- 10 For the assessment of the insecticidal effect of the treatment, all dogs were quantitatively examined for flea infestation prior to the treatment and then in each case 24 hours after treatment or after each flea reinfestation. The endoparasitocidal activity was determined by counting the worms that were excreted with the faeces before and after the treatment (day 1-3 after treatment).

Results

- 15 In all test groups, an insecticidal activity of 100% was detected over a period of 28 days. The endoparasitocidal activity depends on the dose, see the table below.

20

Formulation (% Imidacloprid/% Ivermectin)	Activity
10/0.006	60 %
10/0.05	95 %
10/0.2	99 %

30725-187

- 34 -


CLAIMS:

1. Use of a combination of:

(a) an avermectin, a
22,23-dihydroavermectin B₁ or a milbemycin, and

5 (b) an agonist or antagonist of the
nicotinergetic acetylcholine receptor of an insect
for controlling an ectoparasite and an endoparasite,

wherein the agonist or antagonist of the
nicotinergetic acetylcholine receptor of an insect is a
10 compound of the formula (I):



wherein:

R is: (i) H, or (ii) an optionally substituted
acyl, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl
radical;

15 A is: (i) a monofunctional group, which is H,
optionally substituted acyl, optionally substituted alkyl or
optionally substituted aryl, or (ii) an optionally
substituted bifunctional group optionally interrupted by a
N, O or S heteroatom and which group is linked to the
20 radical Z;

E is an electron-withdrawing radical;

X is -CH= or =N-, wherein -CH= is optionally
linked to the radical Z instead of an H atom; and

30725-187

- 35 -

Z is: (i) a monofunctional group, which is an alkyl, -O-R, -S-R or -N(R)(R) group, wherein R is as defined above, or (ii) a bifunctional group linked to the radical A or the radical X.

5 2. Use of a combination of:


(a) an avermectin, a 22,23-dihydroavermectin B₁ or a milbemycin, and

(b) an agonist or antagonist of the nicotinic acetylcholine receptor of an insect

10 for preparing a medicament for controlling an ectoparasite and an endoparasite,

wherein the agonist or antagonist of the nicotinic acetylcholine receptor of an insect is a compound of the formula (I):

15



wherein:

R is: (i) H, or (ii) an optionally substituted acyl, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl radical;

20 A is: (i) a monofunctional group, which is H, optionally substituted acyl, optionally substituted alkyl or optionally substituted aryl, or (ii) an optionally substituted bifunctional group optionally interrupted by a

30725-187

- 36 -


N, O or S heteroatom and which group is linked to the radical Z;

E is an electron-withdrawing radical;

X is -CH= or =N-, wherein -CH= is optionally
5 linked to the radical Z instead of an H atom; and

Z is: (i) a monofunctional group, which is an alkyl, -O-R, -S-R or -N(R)(R) group, wherein R is as defined above, or (ii) a bifunctional group linked to the radical A or the radical X.

10 3. The use of claim 1 or 2, wherein the avermectin or 22,23-dihydroavermectin B₁ is a compound of the general formula (Ia):



wherein:

X is a single or double bond between the C₂₂ and C₂₃ positions, and the moiety -C₂₂(H)R¹-X-C₂₃(H)R²-, R³ and R⁴ are as defined in the following table:

25

30725-187

- 37 -

	$-C_{22}(H)R^1-X-C_{23}(H)R^2-$	R^3	R^4
Avermectin A _{1a}	-CH=CH-	-sec-Bu	-Me
Avermectin A _{1b}	-CH=CH-	-iso-Pr	-Me
Avermectin A _{2a}	-CH ₂ -CHOH-	-sec-Bu	-Me
Avermectin A _{2b}	-CH ₂ -CHOH-	-iso-Pr	-Me
Avermectin B _{1a}	-CH=CH-	-sec-Bu	-H
Avermectin B _{1b}	-CH=CH-	-iso-Pr	-H
Avermectin B _{2a}	-CH ₂ -CHOH-	-sec-Bu	-H
Avermectin B _{2b}	-CH ₂ -CHOH-	-iso-Pr	-H
22,23-Dihydroavermectin B _{1a}	-CH ₂ -CH ₂ -	-sec-Bu	-H
22,23-Dihydroavermectin B _{1b}	-CH ₂ -CH ₂ -	-iso-Pr	-H
Doramectin	-CH=CH-	-Chx	-H

wherein sec-Bu represents secondary butyl, iso-Pr represents isopropyl, Chx represents cyclohexyl and Me represents methyl.


5 4. The use of claim 3, wherein the avermectin or 22,23-dihydroavermectin B₁ is Avermectin B_{1a}/B_{1b}, 22,23-Dihydroavermectin B_{1a}/B_{1b} or Doramectin.

5. The use of claim 1 or 2, wherein the milbemycin is a compound of the formula (IIa):



. 30725-187

- 38 -

5



wherein R^1 to R^5 are each as defined in the following table:

Macrocyclic lactone	R^1	R^2	R^3	R^4	R^5
Milbemycin B41 D	-H	-H	-iso-Pr	-H	-H
Nemadectin	-H	-OH		-H	-H
Moxidectin	-H	=N-O-Me		-H	-H

10

wherein iso-Pr represents isopropyl and Me represents methyl.

6. The use of claim 5, wherein the milbemycin is Moxidectin.

15 7. The use of any one of claims 1 to 6, wherein for R:

. 30725-187

- 39 -

the acyl is optionally substituted formyl, alkylcarbonyl, arylcarbonyl, alkylsulphonyl, arylsulphonyl or (alkyl-)-(aryl-)-phosphoryl;

the alkyl is optionally substituted C₁₋₁₀-alkyl;

5 the aryl is optionally substituted phenyl or naphthyl;

the aralkyl is optionally substituted phenylmethyl or phenethyl;

10 the heteroaryl is optionally substituted heteroaryl having up to 10 ring atoms and N, O and S as heteroatoms; and

the heteroarylalkyl is optionally substituted heteroarylmethyl or heteroarylethyl having up to 6 ring atoms and N, O and S as heteroatoms.

15 8. The use of claim 7, wherein:

the alkyl is optionally substituted C₁₋₄-alkyl;

the aryl is optionally substituted phenyl;

20 the heteroaryl is optionally substituted heteroaryl having up to 10 ring atoms and N as heteroatom(s); and

the heteroarylalkyl is heteroarylmethyl or heteroarylethyl having up to 6 ring atoms and N as heteroatom(s).

25 9. The use of claim 7, wherein the heteroaryl is optionally substituted thienyl, furyl, thiazolyl, imidazolyl, pyridyl or benzthiazolyl.

30725-187

- 40 -

10. The use of claim 8, wherein the alkyl is optionally substituted methyl, ethyl, i-propyl, or sec- or t-butyl.

11. The use of any one of claims 1 to 10, wherein the
5 optional substituents for R are alkyl, alkoxy, alkylthio, halogenoalkyl, hydroxyl, a halogen atom, cyano, nitro, amino, monoalkyl- or dialkylamino, carboxyl, carbalkoxy, sulpho (-SO₃H), alkylsulphonyl, arylsulphonyl, heteroaryl amino or heteroarylalkyl amino.

10 12. The use of claim 11, wherein the optional substituents for R are C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, C₁₋₄-halogenoalkyl having 1 to 5 halogen atoms, F, Cl, Br, monoalkyl- or dialkylamino having 1 to 4 carbon atoms per
15 alkyl group, C₂₋₄-carbalkoxy, C₁₋₄-alkylsulphonyl, C₆₋₁₀- arylsulphonyl, chloropyridyl amino or chloropyridyl methyl amino.

13. The use of claim 12, wherein the optional substituents for R are C₁₋₂-alkyl, C₁₋₂-alkoxy, C₁₋₂-alkylthio, C₁₋₂-halogenoalkyl having 1 to 3 halogen atoms, monoalkyl- or
20 dialkylamino having 1 to 2 carbon atoms per alkyl group, C₂₋₃-carbalkoxy, C₁₋₂-alkylsulphonyl or phenylsulphonyl.

14. The use of claim 12 or 13, wherein the halogen atoms of the halogenoalkyl group are identical or different and are F, Cl or Br.

25 15. The use of claim 14, wherein the halogen atoms are F.

16. The use of any one of claims 1 to 15, wherein for A, acyl, alkyl and aryl are as defined in claim 7, 8 or 10, and the optional substituents are as defined in any one of
30 claims 11 to 15.

. 30725-187

- 41 -

17. The use of any one of claims 1 to 15, wherein for A, the bifunctional group is C₁₋₄-alkylene and the optional substituents are as defined in any one of claims 11 to 15.

18. The use of claim 17, wherein the bifunctional
5 group is C₁₋₂-alkylene.

19. The use of any one of claims 1 to 18, wherein E is NO₂, CN or a halogenoalkylcarbonyl.

20. The use of claim 19, wherein the halogenoalkylcarbonyl is a 1,5-halogeno-C₁₋₄-carbonyl.

10 21. The use of claim 19, wherein the halogenoalkylcarbonyl is COCF₃.

22. The use of any one of claims 1 to 21, wherein X is -CH= or -N=.

23. The use of any one of claims 1 to 22, wherein Z is
15 (i) and R is as defined in any one of claims 7 to 10, and optional substituents of R are as defined in any one of claims 11 to 15.

24. The use of any one of claims 1 to 22, wherein Z is (ii), wherein A and Z together with the atoms to which they
20 are bonded form a saturated or unsaturated heterocyclic ring.

25. The use of claim 24, wherein the heterocyclic ring further contains 1 or 2 identical or different heteroatoms, hetero groups or a combination thereof.

25 26. The use of claim 25, wherein the heteroatoms are selected from the group consisting of N, O and S, and the hetero group is N-alkyl.

30725-187

- 42 -

27. The use of claim 26, wherein the alkyl of the N-alkyl group has 1 to 4 carbon atoms.

28. The use of claim 27, wherein the alkyl of the N-alkyl group has 1 or 2 carbon atoms.


5 29. The use of any one of claims 24 to 28, wherein the heterocyclic ring has 5 to 7 ring atoms.

30. The use of claim 29, wherein the heterocyclic ring has 5 or 6 ring atoms.


31. The use of any one of claims 1 to 22, wherein Z is
10 (ii), X is =CH-, and Z and X and the atoms to which they are bonded form a saturated or unsaturated heterocyclic ring.

32. The use of claim 31, wherein the heterocyclic ring is as defined in any one of claims 25 to 30.

33. The use of any one of claims 1 to 6, wherein the
15 compound of the formula (I) is:



or







30725-187





- 43 -

wherein A, E, X and Z are as defined in any one of claims 1 and 16 to 32, subst. is a substituent as defined in any one of claims 11 to 15, and n is 1 or 2.

34. The use of any one of claims 1 to 6, wherein the
5 compound of the formula (I) is:













AkD 1022







30725-187

- 44 -




.. 30725-187

- 45 -



15 or



35. The use of claim 34, wherein the compound of the
 20 formula (I) is imidacloprid, AkD 1022 or Ti 435.

.. 30725-187


- 46 -

36. A composition for controlling an ectoparasite and an endoparasite, the composition comprising:

(a) an avermectin, a 22,23-dihydroavermectin B₁ or a milbemyacin, and

5 (b) an agonist or antagonist of the nicotinergetic acetylcholine receptor of an insect

wherein the agonist or antagonist of the nicotinergetic acetylcholine receptor of an insect is a compound of the formula (I):



10 wherein:

R is: (i) H, or (ii) an optionally substituted acyl, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl radical;

15 A is: (i) a monofunctional group, which is H, optionally substituted acyl, optionally substituted alkyl or optionally substituted aryl, or (ii) an optionally substituted bifunctional group optionally interrupted by a N, O or S heteroatom and which group is linked to the radical Z;

20 E is an electron-withdrawing radical;

X is -CH= or =N-, wherein -CH= is optionally linked to the radical Z instead of an H atom; and

Z is: (i) a monofunctional group, which is an alkyl, -O-R, -S-R or -N(R)(R) group, wherein R is as defined


. 30725-187

- 47 -

above, or (ii) a bifunctional group linked to the radical A or the radical X.

37. The composition according to claim 36, further comprising a diluent and/or excipient.

5 38. The composition according to claim 36 or 37, comprising an avermectin or a 22,23-dihydroavermectin B₁, which is a compound of the formula (Ia):



wherein:

X is a single or double bond between the C₂₂ and C₂₃ positions, and the moiety -C₂₂(H)R¹-X-C₂₃(H)R²-, R³ and R⁴ are as defined in the following table:

30725-187

- 48 -

	$-C_{22}(H)R^1-X-C_{23}(H)R^2-$	R^3	R^4
Avermectin A _{1a}	-CH=CH-	-sec-Bu	-Me
Avermectin A _{1b}	-CH=CH-	-iso-Pr	-Me
Avermectin A _{2a}	-CH ₂ -CHOH-	-sec-Bu	-Me
Avermectin A _{2b}	-CH ₂ -CHOH-	-iso-Pr	-Me
Avermectin B _{1a}	-CH=CH-	-sec-Bu	-H
Avermectin B _{1b}	-CH=CH-	-iso-Pr	-H
Avermectin B _{2a}	-CH ₂ -CHOH-	-sec-Bu	-H
Avermectin B _{2b}	-CH ₂ -CHOH-	-iso-Pr	-H
22,23-Dihydroavermectin B _{1a}	-CH ₂ -CH ₂ -	-sec-Bu	-H
22,23-Dihydroavermectin B _{1b}	-CH ₂ -CH ₂ -	-iso-Pr	-H
Doramectin	-CH=CH-	-Chx	-H

wherein sec-Bu represents secondary butyl, iso-Pr represents isopropyl, Chx represents cyclohexyl and Me represents
5 methyl.

39. The composition according to claim 36, 37 or 38, comprising avermectin B_{1a}, avermectin B_{1b} or a mixture of avermectin B_{1a} and avermectin B_{1b}.

40. The composition according to claim 36, 37 or 38,
10 comprising 22,23-dihydroavermectin B_{1a}, 22,23-dihydroavermectin B_{1b} or a mixture of 22,23-dihydroavermectin B_{1a} and 22,23-Dihydroavermectin B_{1b}.


41. The composition according to claim 36, 37 or 38, comprising a mixture of 22,23-dihydroavermectin B_{1a} and
15 22,23-dihydroavermectin B_{1b}.

42. The composition according to claim 36, 37 or 38, comprising doramectin.

30725-187



- 49 -

43. The composition according to claim 36 or 37, comprising a milbemycin, which is a compound of the formula (IIa):



(IIa)

wherein R^1 to R^5 are each as defined in the following table:

Macrocyclic lactone	R^1	R^2	R^3	R^4	R^5
Milbemycin B41 D	-H	-H	-iso-Pr	-H	-H
Nemadectin	-H	-OH		-H	-H
Moxidectin	-H	=N-O-Me		-H	-H

wherein iso-Pr represents isopropyl and Me represents methyl.

44. The composition according to claim 36, 37 or 43, wherein the milbemycin is moxidectin.

30725-187

- 50 -

45. The composition according to any one of claims 36 to 44, wherein in the compound of the formula (I), R is:

H;

optionally substituted formyl, alkylcarbonyl,
5 arylcarbonyl, alkylsulphonyl, arylsulphonyl or (alkyl-)-
(aryl-)-phosphoryl;

optionally substituted C₁₋₁₀-alkyl;

optionally substituted phenyl or naphthyl;

optionally substituted phenylmethyl or phenethyl;

10 optionally substituted heteroaryl having up to 10
ring atoms and N, O and/or S as heteroatoms; or

optionally substituted heteroarylmethyl or
heteroarylethyl having up to 6 ring atoms and N, O and S as
heteroatoms.

15 46. The composition according to any one of claims 36
to 44, wherein in the compound of the formula (I), R is:

H;

optionally substituted C₁₋₄-alkyl;

optionally substituted phenyl;

20 optionally substituted heteroaryl having up to 10
ring atoms and one or more N heteroatoms; and

heteroarylmethyl or heteroarylethyl having up to 6
ring atoms and one or more N heteroatoms.

47. The composition according to claim 45, wherein the
25 optionally substituted heteroaryl is optionally substituted

30725-187

- 51 -

thienyl, furyl, thiazolyl, imidazolyl, pyridyl or
benzothiazolyl.

48. The composition according to claim 45, 46 or 47,
wherein the optionally substituted alkyl is optionally
5 substituted methyl, ethyl, i-propyl, sec-butyl or t-butyl.

49. The composition according to any one of claims 36
to 48, wherein in the compound of formula (I), A is:

H;

optionally substituted formyl, alkylcarbonyl,
10 arylcarbonyl, alkylsulphonyl, arylsulphonyl or (alkyl-)-
(aryl-)-phosphoryl;

optionally substituted C₁₋₁₀-alkyl;

optionally substituted phenyl or naphthyl; or

optionally substituted C₁₋₄-alkylene.

15 50. The composition according to any one of claims 36
to 48, wherein in the compound of formula (I), A is:

H;

optionally substituted C₁₋₄-alkyl;

optionally substituted phenyl; or

20 optionally substituted C₁₋₂-alkylene.

51. The composition according to claim 49 or 50,
wherein the optionally substituted alkyl is optionally
substituted methyl, ethyl, i-propyl, sec-butyl or t-butyl.

52. The composition according to any one of claims 36
25 to 51, wherein in the compound of formula (I), the optional
substituents for R and A are alkyl, alkoxy, alkylthio,

30725-187

- 52 -

halogenoalkyl, hydroxyl, a halogen atom, cyano, nitro, amino, monoalkyl- or dialkylamino, carboxyl, carbalkoxy, -SO₃H, alkylsulphonyl, arylsulphonyl, heteroaryl amino or heteroarylalkylamino.

5 53. The composition according to claim 52, wherein the optional substituents for R and A are C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, C₁₋₄-halogenalkyl having 1 to 5 halogen atoms, F, Cl, Br, monoalkyl- or dialkylamino having 1 to 4 carbon atoms per alkyl group, C₂₋₄-carbalkoxy, C₁₋₄-alkylsulphonyl,
10 C₆₋₁₀-aryl sulphonyl, chloropyridyl amino or chloropyridyl methyl amino.

54. The composition according to claim 53, wherein the optional substituents for R and A are C₁₋₂-alkyl, C₁₋₂-alkoxy, C₁₋₂-alkylthio, C₁₋₂-halogenoalkyl having 1 to 3 halogen
15 atoms, monoalkyl- or dialkylamino having 1 to 2 carbon atoms per alkyl group, C₂₋₃-carbalkoxy, C₁₋₂-alkylsulphonyl or phenylsulphonyl.

55. The composition according to claim 53 or 54, wherein the halogen atoms of the halogenoalkyl group are
20 identical or different and are F, Cl or Br.

56. The composition according to claim 55, wherein the halogen atoms are F.

57. The composition according to any one of claims 36 to 56, wherein E is NO₂, CN or a halogenoalkylcarbonyl.

25 58. The composition according to claim 57, wherein the halogenoalkylcarbonyl is a 1,5-halogeno-C₁₋₄-carbonyl.

59. The composition according to claim 57, wherein the halogenoalkylcarbonyl is COCF₃.

30725-187

- 53 -

60. The composition according to any one of claims 36 to 59, wherein X is -CH=.

61. The composition according to any one of claims 36 to 59, wherein X is -N=.

5 62. The composition according to any one of claims 36 to 61, wherein Z is an alkyl, -O-R, -S-R or -N(R)(R) group, wherein R is as defined in any one of claims 45 to 48, and the optional substituents of R are as defined in any one of claims 52 to 56.

10 63. The composition according to any one of claims 36 to 61, wherein Z is a bifunctional group, and wherein A and Z together with the atoms to which they are bonded form a saturated or unsaturated heterocyclic ring.

64. The composition according to any one of claims 36
15 to 59, wherein Z is a bifunctional group, X is =CH-, and Z and X and the atoms to which they are bonded form a saturated or unsaturated heterocyclic ring.

65. The composition according to claim 63 or 64,
wherein the heterocyclic ring contains 1 or 2 identical or
20 different heteroatoms, hetero groups or a combination thereof.

66. The composition according to claim 65, wherein each heteroatom is N, O or S, and the hetero group is N-alkyl.

25 67. The composition according to claim 66, wherein the alkyl of the N-alkyl group has 1 to 4 carbon atoms.

68. The composition according to claim 67, wherein the alkyl of the N-alkyl group has 1 or 2 carbon atoms.


30725-187

- 54 -


69. The composition according to any one of claims 63 to 68, wherein the heterocyclic ring has 5 to 7 ring atoms.

70. The composition according to claim 69, wherein the heterocyclic ring has 5 or 6 ring atoms.

5 71. The composition according to any one of claims 36 to 44, wherein the compound of the formula (I) is:



or











wherein A, E, X and Z are as defined in any one of claims 36 and 49 to 70, subst. is a substituent as defined in any one
 10 of claims 52 to 56, and n is 1 or 2.

30725-187











- 55 -

72. The composition according to any one of claims 36 to 44, wherein the compound of formula (I) is:







30725-187

- 56 -




30725-187

- 57 -



15 or




Ti 435

20

30725-187


- 58 -

73. The composition according to any one of claims 36 to 44, wherein the compound of formula (I) is imidacloprid:




5

74. The composition according to any one of claims 36 to 44, wherein the compound of formula (I) is AkD1022:



75. The composition according to any one of claims 36 to 44, wherein the compound of formula (I) is Ti435:



76. The composition according to any one of claims 36 to 75, which is a liquid topical solution.

77. The composition according to any one of claims 36 to 75 for topical application to a cat or dog.

78. The composition according to any one of claims 36 to 75 for topical application to specific areas of the dermis of a dog.

20

30725-187

- 59 -

79. The composition according to any one of claims 36 to 75 for topical application to specific areas of the dermis of a cat.

80. The composition according to any one of claims 36 to 79, which is a pour on or spot-on formulation.

81. The composition according to claim 80, which is a spot-on formulation.

82. The composition according to any one of claims 36 to 81, wherein the ectoparasite is a flea.

83. The composition according to any one of claims 36 to 82, wherein the endoparasite is a worm.

84. The composition according to claim 83, wherein the worm is a round worm, hook worm or whip worm.

85. A combination of:

(a) an avermectin, a 22,23-dihydroavermectin B₁ or a milbemyacin; and

(b) an agonist or antagonist of the nicotinic acetylcholine receptor of an insect

as defined in any one of claims 1 to 35, for controlling an ectoparasite and an endoparasite.

86. A combination of:

(a) an avermectin, a 22,23-dihydroavermectin B₁ or a milbemyacin; and

(b) an agonist or antagonist of the nicotinic acetylcholine receptor of an insect as defined in any one of claims 1 to 35,

30725-187

- 60 -

for preparing a medicament for controlling an ectoparasite and an endoparasite.

87. Use of a composition as defined in any one of claims 36 to 84, for controlling an ectoparasite and an
5 endoparasite.

88. Use of a composition as defined in any one of claims 36 to 75, for preparing a medicament for controlling an ectoparasite and an endoparasite.

89. A commercial package comprising a combination of
10 an avermectin, a 22,23-dihydroavermectin B₁ or a milbemycin and an agonist or antagonist of the nicotinergetic acetylcholine receptor of an insect as defined in any one of claims 1 to 35, and associated therewith instructions for controlling an ectoparasite and an endoparasite.

15 90. A commercial package comprising a composition as defined in any one of claims 36 to 84, and instructions for the use therefore for controlling an ectoparasite and an endoparasite.

FETHERSTONHAUGH & CO.

OTTAWA, CANADA

PATENT AGENTS